Methods: Patients with PsA over the age of 18-year-old who met the CASPAR classification criteria were underwent clinical and laboratory evaluation by using standardized protocol and case report form, from two universities outpatient's clinics. PtGA and PhGA, VAS-pain, fatigue, BASDAI, BASFI, health-related QoL were recorded at baseline visit. Pearson correlation coefficient were calculated for PtGA and PhGA. Linear regression model were used to asses relationship between global assessments and clinical finding. Results: A total 144 patients with PsA (male 51, female 93) were included. Symptom duration (7.8±7.5 vs 11.3±11.2), VAS-pain (4.4±2.6 vs 4.9±2.6), PtGA (4.7±2.5 vs 5.0±2.4) and PhGA (4.0±2.2 vs 4.4±2.2) were similar between male and female patients with PsA (p>0.05). VAS-fatigue was higher in female patients with PsA than male ones (5.9±2.7 vs 4.4±2.8, p=0.001). Disease activity measurements such as, tender and swollen joint count, DAS28, BASDAI and acute phase reactant were similar for both sex. Correlation coefficient of Physician's global assessment was higher than PtGA in various clinical findings. The highest correlation coefficient was observed in VAS-pain (r=0.784) and followed by SF36-bodily pain (r=-0.613), BASDAI (r=0.587), NHP-physical activity (r=0.584), VAS-fatigue (r=0.555), BASFI question 5 (r=0.551) for PhGA (p<0.0001). However the highest correlation coefficient was observed in VAS-pain (r=0.690) and followed by NHP-physical activity (r=0.536), BASFI question 10 (r=0.512), BASDAI (r=0.499), SF36 (r=-0.490) and BASFI total score (r=0.484) for PtGA (p<0.0001). Statistically significant positive linear relation was observed between global assessment and clinical parameters (VAS-pain, fatigue, BASDAI, BASFI, DAS28, NHP-physical activity) by using simple linear regression model. VAS-pain and BASDAI question 1 explained 83.3% of PtGA as a predictor in multiple linear regression model. However, VAS-pain and DAS28 explained 68.4% of PhGA as a predictor in multiple linear regression model (table 1) .
Background: Methotrexate (MTX) is the cornerstone in rheumatic diseases, including psoriatic arthritis (PsA), but the complexity of PsA and the paucity of randomised controlled studies and strategic trials need a clear analysis. Objectives: To develop recommendations for the management of MTX in PsA (musculoskeletal manifestations) based on best evidence and experience Methods: The coordinators formulated 14 questions about MTX use (indications, efficacy, safety) in patients with PsA. A systematic literature review was performed to answer these questions. Using this information, inclusion and exclusion criteria were stablished as well as the search strategies (Medline, Embase and the Cochrane Library), that were designed by an expert librarian. Two different reviewers selected the articles, first by title and abstract, then by detailed review, and collected data independently. Evidence tables were produced. With this evidence the coordinators proposed 12 preliminary recommendations that will be discussed and voted in a nominal group of expert meeting. The level of evidence and grade of recommendation will be defined using the Oxford Center for Evidence Based Medicine. Agreement will be stablished if at least 80% of the experts voted yes (yes/no). Results: A total of 12 preliminary recommendations on the use of MTX in PsA were proposed (see Background: Increased large arteries wall stiffness (AS) is a well known independent morbidity and mortality cardiovascular risk factor, not only related to hypertension and diabetets, but also induced by long standing systemic inflammation, as observed in inflammatory rheumatic or gut chronic diseases. Psoriatic arthritis (PsA) was also shown to increase cadiovascular morbidity, but this observation was commonly related with the associated occurrence of long term arthritis, disease activity and CV traditional risk factors Objectives: To assess whether in a selected group of PsA patients, affected by recent onset (4-12 months) arthritis, not suffering from CV disease risk factors, evidence could be obtained of an early alteration of arterial wall function as expressed by an increased arterial pulse wave velocity (aPWV) and secondary reduced tonometric subendocardial viability ratio (tSEVR 
